Atopic Dermatitis Disease Activity and Initiation of Systemic Therapy in the Real-World Setting

An OMNY Health™ Poster

The product of body surface area (BSA) and Physician Global Assessment (PGA) (BSA x PGA) has demonstrated promise as a marker of disease activity (DA) and may be pragmatic in clinical practice given the ease of collection compared to other clinical trial outcome measures.

On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.


  • The BSA x PGA product shows promise as a single metric to measure DA in
    AD patients given the ability to predict STI.
  • Given the complexity of collecting clinical trial outcome measures in AD
    patients during routine clinical practice, the BSA x PGA product appears to
    be a pragmatic solution in generating real-world evidence for AD.


Check Out More Events & Webinars…


By continuing to use the site, you agree to the use of cookies. More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below, then you are consenting to this.